Abstract
A prolific scientific literature attributes pro-or anti-oncogenic properties to many human microRNAs ("miRNAs"). While many of these studies are based on unpersuasive analyses, one candidate suppressor tumor miRNA, miR-34a, appeared convincing enough to be administered to human patients in a clinical trial-with disappointing outcomes. Here we review possible reasons for that failure, and their implications for other miRNAs.